Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Anti‐TNF‐α Treated Patients

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

2003 • 1,750 citations

Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteria

1996 • 1,548 citations

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial

2006 • 1,041 citations

The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis

2000 • 638 citations

Predictors of response to anti-TNF- therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

2006 • 598 citations

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials

2000 • 535 citations

Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP)

2004 • 447 citations

Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project)

2004 • 399 citations

Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression

2005 • 331 citations

Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis

2003 • 285 citations

Treating rheumatoid arthritis early: A window of opportunity?

2002 • 268 citations

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse

2006 • 267 citations

Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset

2005 • 262 citations

Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF

2004 • 224 citations

Rheumatoid factor: Its nature, specificity, and production in rheumatoid arthritis

1976 • 190 citations

Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

2004 • 187 citations

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

2004 • 166 citations

Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis.

2005 • 158 citations

Anti-tumour necrosis factor therapy in rheumatoid arthritis: an update on safety

2004 • 155 citations

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis

2004 • 151 citations

High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor inhibitors in rheumatoid arthritis

2006 • 134 citations

Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti–cyclic citrullinated peptide antibody

2004 • 130 citations

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.

2005 • 124 citations

Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.

2004 • 120 citations

The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis

2005 • 120 citations

Treatment with tumour necrosis factor antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies

2004 • 108 citations

Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis.

1997 • 79 citations

Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: Specificity and relation with rheumatoid factor

2005 • 77 citations

Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis: Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression

1990 • 75 citations

Induction of autoantibodies during prolonged treatment with infliximab.

2003 • 71 citations

Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab.

2005 • 71 citations

Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment

2005 • 62 citations

Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus.

2004 • 55 citations

IgG and IgM Rheumatoid Factors in Rheumatoid Arthritis

1983 • 54 citations

Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis

2004 • 49 citations

Blockade of tumour necrosis factor significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis

2005 • 46 citations

Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors

2002 • 45 citations

Effects of gold therapy on the synthesis and quantity of serum and synovial fluid IgM, IgG, and IgA rheumatoid factors in rheumatoid arthritis patients

1986 • 34 citations

Inflammatory and immunological parameters of disease activity in rheumatoid arthritis patients treated with minocycline

1996 • 31 citations

IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications.

1996 • 28 citations

Differential effects of therapeutic regimens on specific classes of rheumatoid factor.

1986 • 20 citations

In vitro rheumatoid factor synthesis in patients taking second‐line drugs for rheumatoid arthritis

1988 • 20 citations

IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis

1991 • 17 citations

One year treatment with low dose methotrexate in rheumatoid arthritis: Effect on class specific rheumatoid factors

1993 • 15 citations

Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis.

1995 • 15 citations

Rheumatoid factor isotypes and circulating immune complexes in rheumatoid arthritis.

1990 • 14 citations

ELISA assays for IgM and IgG rheumatoid factors: Their clinical correlations during therapy with slow-acting anti-rheumatic drugs

1987 • 8 citations

Cited By (0)

No citing papers found in database